DE60319983D1 - Universelle Zusammensetzung zur kontrollierten Wirkstoffabgabe enthaltend Chitosan - Google Patents

Universelle Zusammensetzung zur kontrollierten Wirkstoffabgabe enthaltend Chitosan

Info

Publication number
DE60319983D1
DE60319983D1 DE60319983T DE60319983T DE60319983D1 DE 60319983 D1 DE60319983 D1 DE 60319983D1 DE 60319983 T DE60319983 T DE 60319983T DE 60319983 T DE60319983 T DE 60319983T DE 60319983 D1 DE60319983 D1 DE 60319983D1
Authority
DE
Germany
Prior art keywords
active ingredient
controlled release
ingredient containing
containing chitosan
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60319983T
Other languages
English (en)
Other versions
DE60319983T2 (de
Inventor
Adnan Ali Badwan
Mayyas Mohammad Ahma Al-Remawi
Mutaz Bellah A W Sheikh Salem
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jordanian Pharmaceutical Manufacturing Co
Original Assignee
Jordanian Pharmaceutical Manufacturing Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jordanian Pharmaceutical Manufacturing Co filed Critical Jordanian Pharmaceutical Manufacturing Co
Application granted granted Critical
Publication of DE60319983D1 publication Critical patent/DE60319983D1/de
Publication of DE60319983T2 publication Critical patent/DE60319983T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Cosmetics (AREA)
DE60319983T 2003-09-01 2003-09-01 Universelle Zusammensetzung zur kontrollierten Wirkstoffabgabe enthaltend Chitosan Expired - Fee Related DE60319983T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03019532A EP1512394B1 (de) 2003-09-01 2003-09-01 Universelle Zusammensetzung zur kontrollierten Wirkstoffabgabe enthaltend Chitosan

Publications (2)

Publication Number Publication Date
DE60319983D1 true DE60319983D1 (de) 2008-05-08
DE60319983T2 DE60319983T2 (de) 2009-07-23

Family

ID=34130084

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60319983T Expired - Fee Related DE60319983T2 (de) 2003-09-01 2003-09-01 Universelle Zusammensetzung zur kontrollierten Wirkstoffabgabe enthaltend Chitosan

Country Status (5)

Country Link
US (1) US20050281873A1 (de)
EP (1) EP1512394B1 (de)
JP (1) JP2005075831A (de)
AT (1) ATE390127T1 (de)
DE (1) DE60319983T2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5184350B2 (ja) * 2006-05-24 2013-04-17 株式会社明治 液状食品増粘化剤及びその製造法
WO2010062261A1 (en) * 2008-11-29 2010-06-03 The Thailand Research Fund System and method for preparing a controlled releas preparation
CN103211789B (zh) * 2012-01-18 2017-07-11 北京天衡药物研究院有限公司 盐酸氨溴索膜控缓释微丸胶囊
JP6566970B2 (ja) * 2014-06-04 2019-08-28 リカルダ、リミテッド、ライアビリティ、カンパニーＬｉｋａｒｄａ，Ｌｌｃ マイクロカプセル化技術及びその生成物
US10660945B2 (en) 2015-08-07 2020-05-26 Victor Matthew Phillips Flowable hemostatic gel composition and its methods of use
US10751444B2 (en) 2015-08-07 2020-08-25 Victor Matthew Phillips Flowable hemostatic gel composition and its methods of use
CN105380925A (zh) * 2015-12-08 2016-03-09 青岛正大海尔制药有限公司 氨溴索沙丁胺醇控释颗粒
CZ2016539A3 (cs) * 2016-09-05 2018-03-14 Zentiva, K.S. Farmaceutická kompozice obsahující dvě rozdílné účinné látky a způsob její přípravy
CN110179764B (zh) * 2019-06-24 2022-01-11 哈尔滨珍宝制药有限公司 一种盐酸氨溴索片及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3686275T2 (de) * 1985-01-11 1993-03-18 Teijin Ltd Praeparate mit verzoegerter freisetzung.
US5600565A (en) * 1994-12-22 1997-02-04 International Business Machines Corporation Method and apparatus for error reduction in item packaging
US5620706A (en) * 1995-04-10 1997-04-15 Universite De Sherbrooke Polyionic insoluble hydrogels comprising xanthan and chitosan
US5859419A (en) * 1995-09-28 1999-01-12 Sol H. Wynn Programmable multiple company credit card system
CA2243619A1 (fr) * 1998-07-17 2000-01-17 Universite De Sherbrooke Hydrogels polyioniques a base de xanthane et chitosane pour stabilisation et relargage controle des vitamines
US20020029176A1 (en) * 2000-09-01 2002-03-07 Anne Carlson Inventory management system and method

Also Published As

Publication number Publication date
ATE390127T1 (de) 2008-04-15
JP2005075831A (ja) 2005-03-24
US20050281873A1 (en) 2005-12-22
DE60319983T2 (de) 2009-07-23
EP1512394A1 (de) 2005-03-09
EP1512394B1 (de) 2008-03-26

Similar Documents

Publication Publication Date Title
DK1183014T3 (da) Smagsmaskerede orale farmaceutiske sammensætninger med kontrolleret frigivelse
AR036943A1 (es) Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil)fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
NO20016107D0 (no) Mesalazin-kontrollert frigivelse orale farmasöytiske sammensetninger
WO2007000778A3 (en) Modified release pharmaceutical compositions on the basis of two polymers and processes thereof
ATE345114T1 (de) Filmbildende zusammensetzungen aus pektin
ATE493973T1 (de) Irbesartan enthaltende pharmazeutische zusammensetzung
WO2007052125A3 (en) Solid oral pharmaceutical compositions for once daily dosing containing pregabalin, a matrix forming agent and a swelling agent
ATE302616T1 (de) Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe
ATE396712T1 (de) Pharmazeutische zubereitung zur modifizierten freisetzung
WO2007017331A3 (en) Immediate release therapeutic systems for improved oral absorption of 7- [ (e) -tert-butyloxyiminomethyl] camptothecin
EP0966966A3 (de) Nefazodon enthaltende Dosierungsform
DE50005529D1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
DE60319983D1 (de) Universelle Zusammensetzung zur kontrollierten Wirkstoffabgabe enthaltend Chitosan
NO20064808L (no) Orale matrixformuleringer med licarbazepin
AU2003230189A1 (en) Oral controlled release pharmaceutical composition containing metaxalone as active agent
DK1561460T3 (da) Nanopartikler til indgivelse af aktive ingredienser, fremgangsmåde til fremstilling af nævnte partikler og komposition, som omfatter det samme
WO2005107702A3 (en) Sustained release, mucoadhesive vaginal pharmaceutical compositions
DE60202590D1 (de) 2h-1-benzopyran-derivate, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen
WO2004078111A3 (en) Extended release minocycline compositions and processes for their preparation
ES2194793T3 (es) Microcapsulas para la liberacion prolongada de farmacos.
ATE355833T1 (de) Pharmazeutische polymerformulierung zur retardierten freisetzung von terbutalinsulfat
AR104921A2 (es) Formulación farmacéutica con liberación retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil)fenol o una sal farmacéuticamente aceptable del mismo y tabletas para administración oral, que la contienen
DE60108354D1 (de) 2H-1-Benzopyran-Derivative, Prozesse zu ihrer Herstellung und Pharmazeutische Zusammensetzungen
DE60319982D1 (de) Universelle Zusammensetzung zur kontrollierten Wirkstofffreigabe enthaltend Xanthangummi und Natriumalginat
JO2571B1 (en) A general composition of controlled liberation

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee